Plant Bio Technologies
ActivePlant Bio Technologies has been active since 2013 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €240k and a net result of €-30k. Equity is growing by ~41.3% per year across the filed fiscal years. Its solvency ranks better than 32% of 211 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability0▼-4
Solvency33▼-32
Growth78=
Stability100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €6k at 30 days only on tighter terms
Liquidity tight (current ratio 1.01 against 1.51 in 2024), and 77% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Sector 21
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
31 d late
2024
2 d early
2023
on the day
2022
31 d late
2021
31 d late
2020
8 d early
2019
28 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
15-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€240k▼ 11.1%
2024 · €270k
2018: €-391k
2019: €-388k
2020: €-393k
2021: €-165k
2022: €248k
2023: €268k
2024: €270k
2018 → 2025
Total assets
€1.04M▲ 31.2%
2024 · €795k
2018: €6k
2019: €11k
2020: €8k
2021: €243k
2022: €691k
2023: €415k
2024: €795k
2018 → 2025
Net result
€-30k
2024 · €2k
2018: €-95k
2019: €3k
2020: €-5k
2021: €-22k
2022: €413k
2023: €20k
2024: €2k
2018 → 2025
Working capital
€5k▼ 98.3%
2024 · €267k
2018: €-394k
2019: €-388k
2020: €-393k
2021: €-165k
2022: €244k
2023: €263k
2024: €267k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-165k-€248k€268k▲ 8.0%€270k▲ 0.8%€240k▼ 11.1%
Operating result€-21k-€410k€29k▼ 92.9%€-21k€-50k▼ 136%
Net result€-22k-€413k€20k▼ 95.2%€2k▼ 89.4%€-30k
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €50k in 2025 against €21k in 2024; the loss grows and 2025 is the lowest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.04M
Fixed assets
€235k▲ 7,179%
Current assets
€808k▲ 2.0%
Equity and liabilities €1.04M
Equity
€240k▼ 11.1%
Debt
€804k▲ 52.9%
The debt ratio rises from 66.1% to 77.0%: debt grows while equity shrinks.
Key figures and ratios
EBITDA
€-22k▼
2024 · €-20k
Cash flow
€-3k▼
2024 · €3k
Solvency
23.0%▼
2024 · 33.9%
Current ratio
1.01▼
2024 · 1.51
Quick ratio
1.01▼
2024 · 1.51
Debt / equity
3.35▲
2024 · 1.95
ROE
-12.5%▼
2024 · 0.8%
ROA
-2.9%▼
2024 · 0.3%
Interest coverage
-6.16▲
2024 · -33.08
Debt
€804k▲
2024 · €526k
Debt ≤ 1 year
€804k▲
2024 · €526k
Income taxes
€240▼
2024 · €413
Staff costs
€8k▲
2024 · €3k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€795k€1.04M▲
Fixed assets21/28€3k€235k▲
Intangible fixed assets21-€233k
Tangible fixed assets22/27€3k€2k▼
Plant, machinery and equipment23€3k€2k▼
Current assets29/58€792k€808k▲
Amounts receivable within one year40/41€784k€802k▲
Trade receivables40€369k€335k▼
Other amounts receivable41€415k€467k▲
Cash at bank and in hand54/58€8k€6k▼
Deferred charges and accrued income490/1€417€246▼
Equity and liabilities
Total equity and liabilities10/49€795k€1.04M▲
Equity10/15€270k€240k▼
Contributions10/11€313k€313k=
Capital10€313k€313k=
Issued capital100€313k€313k=
Profit (loss) carried forward14€-43k€-73k▼
Amounts payable17/49€526k€804k▲
Amounts payable within one year42/48€526k€804k▲
Trade debts44€20k€272k▲
Suppliers440/4€20k€272k▲
Taxes, remuneration and social security45€344€3k▲
Taxes450/3€344€3k▲
Remuneration and social security454/9-€633
Other amounts payable47/48€506k€528k▲
Income statement
Code20242025
Remuneration, social security and pensions62€3k€8k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1k€27k▲
Other operating charges640/8€3k€661▼
Gross operating margin9900€-15k€-14k▲
Operating profit (loss)9901€-21k€-50k▼
Financial income75/76B€24k€24k▼
Recurring financial income75€24k€24k▼
Financial charges65/66B€596€4k▲
Recurring financial charges65€596€4k▲
Profit (loss) for the period before taxes9903€3k€-30k▼
Income taxes67/77€413€240▼
Profit (loss) for the period9904€2k€-30k▼
Profit (loss) for the period to be appropriated9905€2k€-30k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-43k€-73k▼
Profit (loss) brought forward from the previous period14P€-45k€-43k▲
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
2025
29-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 31 days late
2022
31-12
Financial
Back to profitnet €413k
Net result €413k after 2 loss-making years.
31-12
Financial
Liquidity triplescurrent ratio 1.55
Current ratio from 0.60 to 1.55.
31-12
Financial
Equity above €200kEq €248k
Equity rises from €-165k to €248k.
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
23-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
28-08
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 28 days late
2019
31-12
Financial
Back to profitnet €3k
Net result €3k after one loss-making year.
22-05
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
31-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
26-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
9 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2013
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Poortakkerstraat 219051 GentGround area
5,630 m²
Building footprint
2,545 m²
Volume, LiDAR
22,261 m³
Parcel 44062A0307/00T000, Flanders · tallest building 13.4 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
HQ Biosciences EU
since 20132.258.309.062
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44062A0307/00T000 | Flanders | 5,630 m² | 1 · 2,545 m² | 13.4 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
EQUIBOR
BE 0711.998.905
Manage · Eq €249k
C-THAT
BE 0680.990.181
Hasselt · Eq €252k
LANCEO
BE 0835.404.283
Vorselaar · Eq €253k
TAKEAIR
BE 0658.744.222
Oudenaarde · Eq €226k
PHARMA MAR
BE 0634.863.713
Brussel · Eq €223k
Of 150 companies in sector 21100 we hold annual accounts for 108. 71 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded20-08-2013
Fiscal year end31-12
Activities, NACEBEL
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
72109Other research and development on natural sciences
74909Other professional, scientific and technical activities
74999Other professional, scientific and technical activities
Sources
Crossroads Bank for EnterprisesNational Bank · 12 filingsAddress and cadastre registers
Data from official sources, last processed on 14-09-2026. Scores and ratios are computed by Checked and are not a credit decision.